No Data
No Data
Maxim Group Maintains Avenue Therapeutics(ATXI.US) With Buy Rating
Maxim Group Remains a Buy on Avenue Therapeutics (ATXI)
Avenue Therapeutics Reports Q3 EPS $(1.92) , Consensus (94c)
Avenue Therapeutics | 10-Q: Q3 2024 Earnings Report
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Avenue Therapeutics Incentive Plan Awards Key Executives
No Data
No Data